Study of ORM-1153 for acute myeloid leukemia that has returned
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug called ORM-1153 that targets a marker (CD123) found on AML cells. It is for people whose AML has come back or not responded to standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older (or 19 in some countries).
- You must have acute myeloid leukemia (AML) that has come back after treatment or has not responded to treatment.
- Your leukemia cells must have a specific marker called CD123, which the study drug targets.
- You must be in fairly good general health, able to do light activities and be up and about.
- You must have normal liver, kidney, and blood clotting function.
- You must not have had chemotherapy or other cancer treatment within the last 14 days.
- You must not have had a stem cell transplant in the last 3 months.
- Your white blood cell count must be below 25,000 per microliter.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (called Allo-RevCAR01-T cells) for people with relapsed or hard-to-treat acute myeloid leukemia (AML) that has a marker called CD123. The treatment is given with a separate molecule that helps activate these cells to attack the leukemia. The goal is to see if this approach is safe and can help control the disease.
This trial tests a new drug for people with acute myeloid leukemia (AML) that has come back or hasn't responded to standard therapies, and whose leukemia has certain genetic markers. The drug may target these specific changes to help stop the cancer.
This study tests a new experimental drug (NMS-03597812) for adults with AML that has not responded to or has returned after other treatments. The goal is to see if it is safe and if it can help control the leukemia.
This phase 1 trial tests a new drug called PLM-102 for people with acute myeloid leukemia (AML) that has come back or hasn't responded to standard treatment. The goal is to find the best dose and see if it can help control the leukemia.
This early-phase trial tests an 'off-the-shelf' immune cell treatment (CAR-NK cells) that targets a protein called CD123 on leukemia cells. It's for people with AML that has returned or hasn't responded to standard treatments.
This trial tests new treatment options for people whose acute myeloid leukemia (AML) has either not responded to standard therapy or returned. It aims to find better ways to help those who need new options.
Hear when a new CD123+ Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.